Author views CLYM positively after competitor ZBIO's failed IgG4-RD results and sees subcutaneous administration as a commercial edge.
CLYM — LONG The author argues CLYM's candidate is more like Uplizna, which had strong IgG4-RD results, while competitor ZBIO failed because its construct only inhibits B cells instead of depleting them. CLYM can be administered subcutaneously versus Uplizna's IV, which the author expects to be a large commercial advantage.
The benefit to CLYM is that it can be used Sub-cutaneously. Uplizna is IV. Ease of administration for two very similar drugs can end up being actually a huge difference in commercial success.
ZBIO — AVOID The author argues ZBIO's CD19 autoimmune drug is weak because it inhibits rather than depletes B cells, and its IgG4-RD results were much worse than Uplizna's, so it is no longer a competitive threat.
ZBIO had their results in IgG-4RD and it sucked. Was completely terrible compared to Uplizna's results - and CLYM is more like Uplizna than different.
This Reddit post, published January 06, 2026, features u/IJesusChrist discussing CLYM, ZBIO. 2 trade ideas extracted by AI with direction and confidence scoring.
Speakers: u/IJesusChrist · Tickers: CLYM, ZBIO